Is RXII's Big Phama Deal Back In Play? Print E-mail
By M.E.Garza   
Thursday, 09 September 2010 16:02

Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) closed at $2.30+0.21 (up 10.05%) and reached as high as $2.45 after we alerted our subscribers about the loud and credible chatter we're hearing involving a substantial deal with one of the the world’s largest drugmakers.

According to our sources, this recognized leader in RNAi-based therapeutic discovery and development is close to announcing that they have  reached an agreement with the pharmaceutical company which "has been pushing hard to get into the RNAi space."

The pharmaceutical industry has seen some $230 billion in M&A activity from the top 10 pharmaceutical companies alone since the beginning of 2007, but as we reported just days ago, the largest drug makers are likely to continue making acquisitions and signing pricey partnership deals after struggling to develop new "hit drugs" of their own.

The last time we heard this chatter about RXi Pharmaceuticals Corporation (NASDAQ:RXII), we immediately reported the rumors and the company later acknowledged during a presentation that they were actively exploring some key partnerships. RXII's stock price increased significantly (from $2+ to nearly $9) before trading was halted and RXII announced that it was selling a $16.2 million mix of stock and warrants. According to a source familiar with the negotiations, the potential partnership talks with the big pharma had stalled because management at RXII and it's parent company CYTR felt that they were "negotiating from a position of weakness due to a lack of operating capital."

Just days ago, RXII announced that the Company's President and Chief Executive Officer, Noah D. Beerman, will present and webcast a corporate overview at the Rodman & Renshaw Global Investment conference on Monday, September 13, 2010 at 2:50 p.m. ET in New York City. Will an announcement be made there? Is history repeating itself?

Interestingly, two days ago, Silence Therapeutics plc (AIM: SLN) noted after their recent share price movement that "it had received an approach which may or may not lead to an offer for their Company." As you may know, that company is also considered a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics. Are these two leaders in the field both about to be snatched up by one (or two) of big pharma's biggest players? Will this mark a shift in how the entire RNA interference (RNAi) therapeutics field is viewed by science and the investment community?

Before today's 10% jump, RXII's stock had been climbing very slowly and methodically during the last few sessions. There is no doubt that trading activity and volume are increasing after months of consolidation at the bottom. The relative strength index is climbing nicely and the MACD indicator has just moved into positive territory (see the live chart here:

We feel the stock is acting in a very bullish manner and as such, we are issuing this trade alert. In addition, we fully expect that shares will gap up Friday morning given the price action we observed after the market closed.


Disclosure: Long RXII

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus